Evidence map›Paper›PMID 34820264›Full record

ArticleHeartRhythm case reports2021

Ibrutinib-associated atrial fibrillation treatment with catheter ablation.

Ridhima Kapoor, Muhammad Fazal, Paul Cheng, Ronald Witteles, June-Wha Rhee, Tina Baykaner

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in HeartRhythm case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Cardiovascular Safety of Bruton Tyrosine Kinase Inhibitors: From Ibrutinib to Next-Generation Agents.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026
    Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ridhima KapoorDepartment of Medicine, Stanford University School of Medicine, Stanford, California.
Muhammad FazalDepartment of Medicine, Stanford University School of Medicine, Stanford, California.
Paul ChengDepartment of Medicine, Stanford University School of Medicine, Stanford, California.
Ronald WittelesDepartment of Medicine, Stanford University School of Medicine, Stanford, California.
June-Wha RheeDepartment of Medicine, Stanford University School of Medicine, Stanford, California.
Tina BaykanerDepartment of Medicine, Stanford University School of Medicine, Stanford, California.

Funding

Deep Neural Networks To Treat Atrial FibrillationK23HL145017 · NHLBI · STANFORD UNIVERSITY · PI BAYKANER, TINA · 2019 to 2023
$968k
From Locus to Function: Role of ZEB2 in Human Risk of Coronary Artery DiseaseK08HL153798 · NHLBI · STANFORD UNIVERSITY · PI CHENG, PAUL PO SHENG · 2020 to 2024
$933k
Patient-specific modeling of metabolic dysfunction in statin-induced myopathy using iPSC-derived myocytesK08HL148540 · NHLBI · STANFORD UNIVERSITY · PI RHEE, JUNE-WHA · 2020 to 2024
$760k
NHLBI NIH HHS K08 HL148540NHLBI NIH HHS K08 HL153798NHLBI NIH HHS K23 HL145017
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Atrial fibrillationCatheter ablationIbrutinibLymphomaTyrosine kinase inhibitors

Identifiers

PMID34820264
PMCPMC8602082

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.